Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil and Ketoconazole as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects

Trial Profile

Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil and Ketoconazole as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2013

At a glance

  • Drugs Adomeglivant (Primary) ; Gemfibrozil; Ketoconazole
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2013 Planned number of patients changed from 30 to 45 as reported by ClinicalTrials.gov.
    • 16 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top